Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical trial access for patients.
Clinical Brief: Future Directions in Bronchiectasis Research and Care
Main Discussion Topics
Key Points for Physicians
Notable Insights
The field is shifting from simply categorizing bronchiectasis as CF vs non-CF toward more nuanced phenotyping that enables targeted treatment approaches.
Clinical Significance
The establishment of specialized centers and increased research focus on bronchiectasis represents a significant advancement in addressing this previously underrecognized condition.
Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG
June 12th 2025Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).
Read More
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More